Patient-Centered Treatment Strategies to Improve Outcomes in Schizophrenia
Can a patient-centered approach to treatment be adopted for patients with schizophrenia? Can these patients take part in shared decision-making? Follow along as Dr Harvey shares his expertise.
Schizophrenia is a severe, lifelong disorder that affects cognitive, behavioral, and emotional functioning. Many individuals living with schizophrenia experience numerous relapses and ongoing impairment. To improve the clinical and functional outcomes for people with schizophrenia, clinicians should recognize the importance of adopting a patient-centered approach to treatment. Simplifying the medication regimen, using shared decision-making, and offering psychosocial interventions are strategies that may contribute to better outcomes.
From the Series: Overcoming Adherence Issues and Providing Patient-Centered Care for People Living With Schizophrenia
To cite: Harvey PD. Patient-centered treatment strategies to improve outcomes in schizophrenia. J Clin Psychiatry. 2021;82(2):IC20018BR2C.
To share: https://doi.org/10.4088/JCP.IC20018BR2C
© Copyright 2021 Physicians Postgraduate Press, Inc.
- Psychiatric nurse practitioners (NPs)
- Psychiatric physician assistants (PAs)
Adopt a patient-centered approach to treatment for patients with schizophrenia
Supported by an educational grant from Intra-Cellular Therapies, Inc.
After completing this educational activity, you should be able to:
- Adopt a patient-centered approach to treatment for patients with schizophrenia
Release, Review, and Expiration Dates
This brief report activity was published in March 2021 and is eligible for AMA PRA Category 1 Credit™ through March 31, 2023. The latest review of this material was January 2021.
Statement of Need and Purpose
The goals of schizophrenia treatment are to control symptoms, prevent relapse, and improve functioning and quality of life. For many patients, these goals are not being met. Unfortunately, clinicians often make decisions that are not concordant with clinical evidence or guidelines. Psychiatrists cite personal experience as the factor that most influences their decision-making about treatment for patients with schizophrenia. Clinicians are often not taking a patient-centered approach to schizophrenia treatment selection; thus, patients feel uninvolved in the choice of their treatment and report less satisfaction with care. Guidelines recommend taking into account not only comorbid illness, concurrent medications, previous medication experiences, and side effect profiles but also patient preferences when selecting antipsychotics. Clinicians would benefit from a review of effective, evidence-based care to help patients improve adherence. They also need to know about new agents that may treat a broader range of symptoms and limit side effects that decrease patients’ adherence and must recognize the importance of adopting a patient-centered approach to schizophrenia treatment. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on schizophrenia.
Disclosure of Off-Label Usage
Dr Harvey has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this activity.
The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
This activity is derived from the teleconference series “Overcoming Adherence Issues and Providing Patient-Centered Care for People Living With Schizophrenia,” which was held in October–November 2020 and supported by an educational grant from Intra-Cellular Therapies, Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.
Philip D. Harvey, PhD
University of Miami Miller School of Medicine, Florida
The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The Accreditation Council for Continuing Medical Education (ACCME) defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure is as follows:
Dr Harvey is a consultant for Acadia, Alkermes, BioXcel, Boehringer Ingelheim, Intra Cellular Therapies, Minerva, Regeneron, and Sunovion; has received grant/research support from Stanley Medical Research Institute and Takeda; and has received other financial or material support for the Brief Assessment of Cognition in Schizophrenia.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation